167 related articles for article (PubMed ID: 22886403)
1. The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice.
Wang C; Li H; Chen SG; He JW; Sheng CJ; Cheng XY; Qu S; Wang KS; Lu ML; Yu YC
J Bone Miner Metab; 2012 Nov; 30(6):630-7. PubMed ID: 22886403
[TBL] [Abstract][Full Text] [Related]
2. Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats.
Sedlinsky C; Molinuevo MS; Cortizo AM; Tolosa MJ; Felice JI; Sbaraglini ML; Schurman L; McCarthy AD
Eur J Pharmacol; 2011 Oct; 668(3):477-85. PubMed ID: 21839072
[TBL] [Abstract][Full Text] [Related]
3. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I.
Ackert-Bicknell CL; Shockley KR; Horton LG; Lecka-Czernik B; Churchill GA; Rosen CJ
Endocrinology; 2009 Mar; 150(3):1330-40. PubMed ID: 18948404
[TBL] [Abstract][Full Text] [Related]
4. Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.
Kus V; Flachs P; Kuda O; Bardova K; Janovska P; Svobodova M; Jilkova ZM; Rossmeisl M; Wang-Sattler R; Yu Z; Illig T; Kopecky J
PLoS One; 2011; 6(11):e27126. PubMed ID: 22073272
[TBL] [Abstract][Full Text] [Related]
5. Bone is a target for the antidiabetic compound rosiglitazone.
Rzonca SO; Suva LJ; Gaddy D; Montague DC; Lecka-Czernik B
Endocrinology; 2004 Jan; 145(1):401-6. PubMed ID: 14500573
[TBL] [Abstract][Full Text] [Related]
6. Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants.
Djaouti L; Jourdan T; Demizieux L; Chevrot M; Gresti J; Vergès B; Degrace P
Diabetes Metab Res Rev; 2010 May; 26(4):297-305. PubMed ID: 20503262
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration.
Liu L; Aronson J; Lecka-Czernik B
Bone; 2013 Jan; 52(1):247-58. PubMed ID: 23069375
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
[TBL] [Abstract][Full Text] [Related]
9. [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats].
Chen XP; Yang WY; Bu S; Xiao JZ; Liu XL; Wang N; Zhao WH
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):280-3. PubMed ID: 15130413
[TBL] [Abstract][Full Text] [Related]
10. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin.
Ye JM; Dzamko N; Cleasby ME; Hegarty BD; Furler SM; Cooney GJ; Kraegen EW
Diabetologia; 2004 Jul; 47(7):1306-1313. PubMed ID: 15232684
[TBL] [Abstract][Full Text] [Related]
11. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.
Kanazawa I; Yamaguchi T; Yano S; Yamamoto M; Yamauchi M; Kurioka S; Sugimoto T
Osteoporos Int; 2010 Dec; 21(12):2013-8. PubMed ID: 20130841
[TBL] [Abstract][Full Text] [Related]
12. Exercise Regulation of Marrow Fat in the Setting of PPARγ Agonist Treatment in Female C57BL/6 Mice.
Styner M; Pagnotti GM; Galior K; Wu X; Thompson WR; Uzer G; Sen B; Xie Z; Horowitz MC; Styner MA; Rubin C; Rubin J
Endocrinology; 2015 Aug; 156(8):2753-61. PubMed ID: 26052898
[TBL] [Abstract][Full Text] [Related]
13. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?
Brunmair B; Staniek K; Gras F; Scharf N; Althaym A; Clara R; Roden M; Gnaiger E; Nohl H; Waldhäusl W; Fürnsinn C
Diabetes; 2004 Apr; 53(4):1052-9. PubMed ID: 15047621
[TBL] [Abstract][Full Text] [Related]
16. Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.
Zhao J; Li Y; Zhang H; Shi D; Li Q; Meng Y; Zuo L
J Bone Miner Metab; 2019 Sep; 37(5):805-814. PubMed ID: 30706148
[TBL] [Abstract][Full Text] [Related]
17. Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Retnakaran R; Ye C; Hanley AJ; Harris SB; Zinman B
Diabetes Obes Metab; 2012 Jan; 14(1):91-3. PubMed ID: 21812893
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.
Kubota N; Terauchi Y; Kubota T; Kumagai H; Itoh S; Satoh H; Yano W; Ogata H; Tokuyama K; Takamoto I; Mineyama T; Ishikawa M; Moroi M; Sugi K; Yamauchi T; Ueki K; Tobe K; Noda T; Nagai R; Kadowaki T
J Biol Chem; 2006 Mar; 281(13):8748-55. PubMed ID: 16431926
[TBL] [Abstract][Full Text] [Related]
19. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
[TBL] [Abstract][Full Text] [Related]
20. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
